Neurocrine Biosciences, a leading biopharmaceutical company, has recently announced a settlement in the patent litigation concerning Ingrezza, their flagship product for treating tardive dyskinesia. The litigation was initiated in response to Sandoz and Crystal Pharmaceutical’s submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking approval to manufacture generic versions of Ingrezza.
In the settlement agreement, Neurocrine has agreed to allow Sandoz to sell generic versions of Ingrezza in the United States starting from February 1, 2040, or potentially earlier under specific circumstances. This resolution marks a significant development for Neurocrine as it aims to navigate the complex landscape of patent protection.
While this settlement resolves the dispute with Sandoz and Crystal Pharmaceutical, Neurocrine is still engaged in ongoing patent litigation against two other companies that have filed ANDAs for marketing their own generic versions of Ingrezza. A trial date has been scheduled for January 2, 2024, highlighting the continued efforts by Neurocrine to protect its intellectual property rights.
Ingrezza has been a key revenue driver for Neurocrine, contributing to a substantial portion of the company’s revenue during the second quarter. The product’s sales have experienced a noteworthy increase of 26% compared to the same period last year. Neurocrine remains committed to advancing the field of neuroscience and providing innovative solutions for patients suffering from neurological disorders.